{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicpnwn56bsu45u7t4gfwxpyto7rxommvg543whyiyb4u3dhat5uum",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mghd6xznn522"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifbd4kgurii7fp2ghvqwojsozb3clqlwgf32tcqji2koag76bbnye"
    },
    "mimeType": "image/jpeg",
    "size": 57625
  },
  "path": "/pharmalot/2026/03/06/novo-ozempic-wegovy-generics-patents-glp1/?utm_campaign=rss",
  "publishedAt": "2026-03-06T19:20:26.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharmalot",
    "drug pricing",
    "Novo Nordisk",
    "Obesity",
    "Pharmaceuticals",
    "STAT+",
    "weight loss"
  ],
  "textContent": "Generic versions of Novo Nordisk’s Wegovy and Ozempic medications could be mass produced for about $3 per person a month, according to a new analysis.",
  "title": "STAT+: Novo Nordisk’s Wegovy and Ozempic shots could be made for as little as $3 a month, analysis finds",
  "updatedAt": "2026-03-06T20:02:16.000Z"
}